Antimicrobial resistance in pediatrics

AMR Fundamentals - Superbugs 101

• Antimicrobial Resistance (AMR): Microbe's ability to survive standard antimicrobial exposure.
• Mechanisms:
  • Intrinsic: Natural insensitivity (e.g., Mycoplasma lacks a cell wall, making it resistant to beta-lactams).
  • Acquired: Genetic mutation or Horizontal Gene Transfer (HGT).
    • HGT Methods: Plasmids (conjugation), bacteriophages (transduction), naked DNA uptake (transformation).
• Key Resistance Pathways:
  • Enzymatic Degradation: Beta-lactamases hydrolyzing penicillins.
  • Target Site Alteration: mecA gene in MRSA alters Penicillin-Binding Proteins (PBPs).
  • Efflux Pumps: Actively transport antibiotics out of the cell.

⭐ High-Yield: Plasmid-mediated conjugation is the most common mechanism for transferring resistance genes between bacteria, crucial for the spread of ESBL and carbapenemase resistance.

Resistant Pathogens in India - The Usual Suspects

• Focus on "ESKAPE" pathogens, notorious for multidrug resistance (MDR).
  • 📌 ESKAPE: Enterococcus, Staph. aureus, Klebsiella, Acinetobacter, Pseudomonas, Enterobacter.
• S. aureus: High prevalence of Methicillin-resistance (MRSA). Vancomycin resistance (VRSA) emerging.
• S. pneumoniae: Penicillin and macrolide resistance is widespread.
• Enterobacteriaceae (Klebsiella, E. coli): Extended-Spectrum β-Lactamase (ESBL) production is common. Carbapenem-Resistant Enterobacteriaceae (CRE) is a major threat.
• P. aeruginosa & A. baumannii: Frequently multidrug-resistant (MDR), especially carbapenem-resistant strains in ICUs.
• Enterococcus faecium: Vancomycin-resistant Enterococcus (VRE) is a significant nosocomial pathogen.

⭐ The New Delhi metallo-beta-lactamase (NDM-1) gene, first identified in India, drives widespread carbapenem resistance in Gram-negative bacteria like E. coli and Klebsiella.

AMR in Clinical Syndromes - When Bugs Fight Back

• Neonatal Sepsis: High resistance in Klebsiella, Acinetobacter.
  • Empiric therapy failure is common.
  • Carbapenems (Meropenem, Imipenem) often required.
  • Colistin as a last resort for pan-drug resistance (PDR).
• Community-Acquired Pneumonia (CAP): Penicillin-resistant S. pneumoniae (PRSP).
  • Resistance via altered Penicillin-Binding Proteins (PBPs).
  • Higher doses of Amoxicillin (90 mg/kg/day) can overcome resistance.
  • Ceftriaxone/Cefotaxime for non-responders.
• Enteric Fever (Typhoid): Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Salmonella Typhi is rampant.
  • MDR: Resistant to Ampicillin, Chloramphenicol, Co-trimoxazole.
  • XDR: MDR + Fluoroquinolone + 3rd Gen Cephalosporin resistance.

⭐ Azithromycin is the preferred oral agent for uncomplicated MDR Typhoid fever. For XDR Typhoid, Meropenem is often the treatment of choice, sometimes combined with Azithromycin.

Antimicrobial Stewardship - The Good Fight

• Goal: Optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, primarily resistance.
• The 5 Ds of AMS:
  • Diagnosis: Accurate and timely.
  • Drug: Correct choice, narrowest spectrum.
  • Dose: Optimized based on weight and renal function.
  • Duration: Shortest effective duration.
  • De-escalation: Switch to targeted therapy post-sensitivity results.

⭐ WHO AWaRe Classification: A key stewardship tool categorizing antibiotics into Access, Watch, and Reserve groups to combat resistance.

High‑Yield Points - ⚡ Biggest Takeaways

• Inappropriate antibiotic use, especially for viral infections, is the primary driver of resistance.
• Key resistant pathogens include MRSA, ESBL-producers (E. coli, Klebsiella), and Penicillin-Resistant S. pneumoniae (PRSP).
• For Enteric Fever, widespread fluoroquinolone resistance necessitates using azithromycin or ceftriaxone.
• MDR-TB in children is a growing threat requiring specialized drug regimens and contact tracing.
• Management hinges on antibiotic stewardship and strict adherence to culture sensitivity data.